Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

News Spotlights Stocks

BioMarin Pharma rises on BMO upgrade to outperform

post-img

BioMarin Pharmaceutical (NASDAQ:BMRN) shares rose 2.5% on Wednesday after BMO analysts lifted the rating to Outperform from Market Perform as they see an attractive valuation at current levels.

“We believe that our thesis of a (s)low Roctavian uptake is materializing, as reflected in Roctavian’s slow EU launch and FDA label restrictions. However, at this valuation (-25% since we initiated coverage), we believe that Roctavian constitutes an upside opportunity as it’s largely not priced in,” they said in a note.

Last week, the United States Food and Drug Administration (FDA) approved Roctavian gene therapy for the treatment of adults with severe hemophilia A. The analysts see Roctavian’s “uptake to be (s)lower than consensus expectations.”

“We expect Biomarin’s base business to provide downside protection while positive updates around Voxzogo growth and Roctavian dosing will drive upside. Therefore, we think BMRN’s risk/reward is now skewed to the upside and upgrade BMRN to Outperform,” the analysts concluded.

The stock target remains $102 per share.

Related Post